Business Context and Reporting Period
Company: Insight Molecular Diagnostics Inc. (formerly Oncocyte Corporation; Ticker: IMDX)
Reporting Period: Quarter ended September 30, 2025 (Q3 2025)
Business Overview: iMDx is a diagnostics technology company focused on organ transplant and oncology therapy selection/monitoring. The company operates a CLIA-certified laboratory in Nashville, Tennessee, and an R&D lab in Göttingen, Germany. Key products include the GraftAssureCore (Kidney) lab-developed test (LDT) and the GraftAssureIQ research-use-only (RUO) kit. The company entered a global strategic partnership with Bio-Rad Laboratories in April 2024 to develop and commercialize kitted transplant products.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Net Revenue | $260 | $115 | $2,916 | $395 |
| Gross Profit | $139 | $50 | $1,802 | $145 |
| Net Loss | $(10,854) | $(13,493) | $(27,267) | $(27,152) |
| Diluted EPS | $(0.34) | $(0.98) | $(0.91) | $(2.36) |
| Cash and Cash Equivalents | $18,692 | $8,636 | $18,692 | $8,636 |
| Restricted Cash | $1,518 | $1,700 | $1,518 | $1,700 |
| Total Assets | $43,937 | $35,081 | $43,937 | $35,081 |
| Accumulated Deficit | $(377,806) | $(350,539) | $(377,806) | $(350,539) |
Note: Financial data is presented in thousands. Cash flow from operating activities for the nine months ended September 30, 2025, was a net use of $16.6 million.
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 126% quarter-over-quarter (Q3 2025 vs. Q3 2024) and 638% year-to-date, driven primarily by Laboratory Services revenue ($260k in Q3 2025 vs. $115k in Q3 2024). The company recorded its first Kitted Products revenue of $24k in the nine months ended September 30, 2025.
- Expense Increases: Research and Development (R&D) expenses rose 38% in Q3 and 33% YTD, attributed to professional fees and laboratory costs for GraftAssure and DetermaIO development. Sales and Marketing expenses increased 33% in Q3 and 48% YTD due to commercialization ramp-up.
- Contingent Consideration: The loss from the change in fair value of contingent consideration decreased significantly to $3.4 million in Q3 2025 from $7.1 million in Q3 2024, and $7.1 million YTD 2025 from $9.4 million YTD 2024. This reduction is due to revised estimates regarding future payout probabilities.
- Liquidity Position: Cash and cash equivalents increased to $18.7 million from $8.6 million at year-end 2024, bolstered by a February 2025 registered direct offering that generated approximately $29.1 million in gross proceeds.
Guidance, Outlook, and Risks
- Going Concern: Management has evaluated the company's ability to continue as a going concern. While the company has incurred operating losses since inception, management concluded that substantial doubt does not exist regarding the ability to continue for at least one year following the issuance of the financial statements, based on the February 2025 capital raise and plans to optimize cash burn.
- Strategic Focus: The company is shifting strategic focus from Laboratory Services to commercializing transplant kitted tests (GraftAssureIQ and future IVD GraftAssureDx) and oncology products (DetermaIO). Sales personnel are being deployed to sign new laboratory customers for kitted products.
- Reimbursement: In May 2025, iMDx received a positive coverage decision boosting the reimbursement rate for GraftAssureCore (Kidney) to $2,753 per result. The company is monitoring potential changes to Medicare Administrative Contractor (MAC) policies regarding test frequency caps.
- Regulatory Risks: The FDA revoked a final rule in September 2025 that would have subjected LDTs to medical device regulations, retaining enforcement discretion. However, future regulatory changes remain a risk. The company is also subject to risks associated with government shutdowns impacting FDA review timelines.
- Collaboration Dependency: The company is heavily dependent on its strategic partnership with Bio-Rad for the development and commercialization of kitted products, including supply of instruments and reagents.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $18.7 million cash balance against the projected operating burn rate, considering the company's history of negative operating cash flows.
- Revenue Concentration: Confirm the sustainability of Laboratory Services revenue, which was 100% derived from a single customer in Q3 2025.
- Contingent Consideration Liability: Monitor the $45.0 million total contingent consideration liability (current and noncurrent) and the assumptions used to value future milestone and royalty payments from the IGI and Chronix acquisitions.
- Reimbursement Stability: Track the status of the draft Local Coverage Determination (LCD) regarding caps on surveillance tests for kidney, heart, and lung transplants, which could impact future revenue per patient.
- Capital Requirements: Assess the likelihood of future equity dilution, as the company explicitly states it will need to access additional capital to finance operations and contingent consideration payments.